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Abstract
Aims/hypothesis Obesity is a major risk factor for type 2
diabetes. Recent genome-wide association (GWA) studies
have identified multiple loci robustly associated with BMI
and risk of obesity. However, information on their
associations with type 2 diabetes is limited. Such informa-
tion could help increase our understanding of the link
between obesity and type 2 diabetes. We examined the
associations of 12 obesity susceptibility loci, individually
and in combination, with risk of type 2 diabetes in the
population-based European Prospective Investigation of
Cancer (EPIC) Norfolk cohort.
Methods W eg e n o t y p e d1 2S N P s ,i d e n t i f i e db yG W A
studies of BMI, in 20,428 individuals (aged 39–79 years
at baseline) with an average follow-up of 12.9 years, during
which 729 individuals developed type 2 diabetes. A genetic
predisposition score was calculated by adding the BMI-
increasing alleles across the 12 SNPs. Associations with
incidence of type 2 diabetes were examined by logistic
regression models.
Results Of the 12 SNPs, eight showed a trend with
increased risk of type 2 diabetes, consistent with their
BMI-increasing effects. Each additional BMI-increasing
allele in the genetic predisposition score was associated
with a 4% increased odds of developing type 2 diabetes
(OR 1.041, 95% CI 1.005–1.078; p=0.02). Adjustment for
BMI completely abolished the association with incident
type 2 diabetes (OR 1.003, 95% CI 0.967–1.039; p=0.89).
Conclusions/interpretation The genetic predisposition to
obesity leads to increased risk of developing type 2
diabetes, which is completely mediated by its obesity-
predisposing effect.
Keywords Genetic predisposition.Genome-wide
association studies.Obesity.Type 2 diabetes
Abbreviations
EPIC European Prospective Investigation of Cancer
GWA Genome-wide association
SNP Single nucleotide polymorphism
Introduction
Type 2 diabetes results from a complex interplay between
genetic and environmental factors. Overweight/obesity is a
major risk factor for type 2 diabetes. Longitudinal studies
have consistently shown that obesity-related traits, such as
BMI and waist circumference, are associated with the risk
of type 2 diabetes [1–3]. The rapid increase in the
prevalence of obesity has contributed to the rising preva-
lence of type 2 diabetes over the last three decades [4, 5].
However, not all individuals with type 2 diabetes are obese,
and vice versa, and it is believed that the genetic
architecture of type 2 diabetes in obese individuals is
different from that in non-obese individuals [6, 7].
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Diabetologia (2011) 54:776–782
DOI 10.1007/s00125-011-2044-5Recent large-scale high-resolution genome-wide associ-
ation (GWA) studies have identified at least 12 single
nucleotide polymorphisms (SNPs) in or near the NEGR1,
SEC16B, TMEM18, ETV5, GNPDA2, BDNF, MTCH2,
SH2B1, FAIM2, FTO, MC4R and KCTD15 genes, unequiv-
ocally associated with BMI [8–12]. Among these, the FTO
locus has the largest effect, with each risk allele increasing
BMI by 0.40–0.66 kg/m
2 and obesity risk by 30%. Of
interest is that the FTO locus was first identified by a GWA
study for type 2 diabetes [8]. A more detailed examination
showed that the FTO–type 2 diabetes association was
mediated by the higher BMI observed in type 2 diabetes
cases than in controls as adjustment for BMI abolished the
association between FTO and type 2 diabetes [8]. It is not
known whether most other recently identified obesity
susceptibility loci also increase the risk of type 2 diabetes,
and whether such association is independent of, or
mediated through, BMI. Such information may increase
our understanding of the link between obesity and type 2
diabetes. After all, not all obese individuals have type 2
diabetes and vice versa. Furthermore, the collective
contribution of the obesity susceptibility variants to the
increased risk of type 2 diabetes has not been studied so far.
Thus, in the current study we examined the associations
of the 12 obesity susceptibility loci, individually and in
combination, with the risk of developing type 2 diabetes in
the European Prospective Investigation of Cancer (EPIC)
Norfolk cohort, a population-based cohort with an average
follow-up period of 12.9 years.
Methods
Study participants The EPIC-Norfolk study is a prospec-
tive population-based cohort study of 25,631 residents
living in the city of Norwich and its nearby areas. At
baseline, 21,631 individuals aged 39–79 years, all of white
European origin and unrelated, had DNA available for
genotyping. Of these, we excluded (1) individuals with
missing data for any of the variables studied, including age,
sex, BMI, and genotype data for all 12 SNPs (n=629);
(2) those with an absolute annual change of BMI greater
than 2 kg/m
2 or of waist circumference greater than 7 cm
during a follow-up period of 3–4 years (n=63); and (3)
those with missing status of type 2 diabetes at baseline or
during follow-up (n=20). Of the remaining sample
(n=20,919), 491 had type 2 diabetes at baseline.
Full details of the study have been described previously
[13, 14]. In brief, trained nurses measured height in
centimetres and weight in kilograms and BMI was
calculated as weight in kilograms divided by height in
meters squared.
Individuals were ascertained as incident type 2 diabetes
cases on 30 November 2008 using multiple data sources:
self-report of doctor-diagnosed type 2 diabetes on three
follow-up health and lifestyle questionnaires; HbA1c >7%
at either baseline or follow-up health checks; record linkage
that traced each participant for type 2 diabetes diagnosis to
general practice registers, regional hospital outpatient
diabetes registers, hospital admissions data that linked to
type 2 diabetes; and Office of National Statistics mortality
data with coding for type 2 diabetes. Criteria for qualifying
as a confirmed incident type 2 diabetes case were:
(1) confirmation of self-report by another data source; or
(2) diagnosis captured by an external source alone,
independently of participation in study follow-up question-
naires or visit. A validation study showed that these sources
identified 96% of all known type 2 diabetes cases [15]. In
the sample of 20,428 individuals (excluding 491 type 2
diabetes cases at baseline) with an average follow-up period
of 12.9 years (median 13.3 years, interquartile range
2.1 years), 729 cases of type 2 diabetes were verified.
Descriptive characteristics at baseline of the study
samples, stratified by type 2 diabetes status, are reported
in Table 1. The Norfolk, UK, Health District Ethics
Committee approved the study and all participants gave
their informed written consent.
Genotyping We genotyped SNPs rs3101336, rs10913469,
rs6548238, rs7647305, rs10938397, rs925946, rs10838738,
rs7498665, rs7132908, rs1121980, rs17782313 and
rs368794, in or near the NEGR1, SEC16B, TMEM18,
ETV5, GNPDA2, BDNF, MTCH2, SH2B1, FAIM2, FTO,
MC4R and KCTD15 genes, respectively. These 12 SNPs
had previously been found to be unequivocally associated
with BMI through large-scale GWA studies [8–12]. SNP
information and genotyping methods for the 12 SNPs have
been described previously in detail (see Electronic supple-
Table 1 Characteristics of the study cohort at baseline, stratified by type 2 diabetes status
Variable Non-case Incident case Incident or prevalent case
n 19,699 729 1,220
Men/women, n (%) 9,551/10,148 (48.5/51.5) 450/279 (61.7/38.3) 780/440 (63.9/36.1)
Age (years), mean ± SD 58.6±9.3 61.8±8.3 62.7±8.2
BMI (kg/m
2), mean ± SD 26.2±3.7 29.5±4.3 28.9±4.4
Diabetologia (2011) 54:776–782 777mentary material [ESM] Table 1)[ 16]. All variants met
quality control criteria (call rate >95%, blind duplicate
concordance >97% and genotype distributions in Hardy–
Weinberg equilibrium, p>0.05).
Statistical analyses Genotypes were coded 0, 1 or 2
according to the number of BMI-increasing alleles for each
SNP, with the BMI-increasing alleles defined by the results
reported by recent GWA studies [8–12]. We used a general
linear model to examine the effect size of each individual
variant on BMI, adjusted for age and sex. A logistic
regression model was used to examine the association of
BMI (as a continuous trait) and each individual variant with
the risk of developing type 2 diabetes during follow-up,
with age and sex included in the model as covariates.
To examine the collective contribution of the 12 variants,
we calculated a genetic predisposition score for each
individual by summing the BMI-increasing alleles across
the 12 SNPs. The BMI-increasing alleles were not weighted
based on their individual effect sizes as we and others have
shown that weighting of risk alleles has no material impact
on the results [16, 17]. For individuals with missing
genotypes for three or fewer SNPs, missing genotype data
were replaced with the average allele count of the
respective SNP for the purpose of calculating the genetic
predisposition score. Individuals with missing genotypes
for more than three SNPs were excluded, which resulted in
a total sample of 20,026 individuals (i.e. 97.3% of the total
sample) with a genetic predisposition score. Subsequently,
we repeated the analyses with the genetic predisposition
score in the same way as we did with each individual SNP.
For associations of individual SNPs or the genetic
predisposition score with type 2 diabetes, analyses were
further adjusted for BMI to examine whether the associa-
tions of individual SNPs or of the genetic predisposition
score with type 2 diabetes were mediated by their effects on
BMI. Abolishment of association between the SNPs or
genetic predisposition with type 2 diabetes after adjustment
for BMI would be suggestive of causality between BMI and
type 2 diabetes. This determination is typically referred to
as instrumental variable analysis or Mendelian random-
isation [18, 19]. To further examine whether the observed
effect of individual variants or the genetic predisposition
score on incident type 2 diabetes was in agreement with the
expected effect based on the effect size of individual SNPs
or of the score on BMI and the effect size of BMI on type 2
diabetes, we calculated the expected effect size according to
the formula "E ¼ "GB   "BD, where βE is the expected
effect size of each individual SNP or the genetic predispo-
sition score on type 2 diabetes (lnOR), βGB is the effect size
of each individual SNP or the score on BMI, and βBD is the
effect size of BMI on type 2 diabetes (lnOR); the variance
of βE was calculated as SEGB
2   "BD
2 þ SEBD
2   "GB
2.
SEs are standard errors for the respective β values. Then,
βE and the observed βO (lnOR of each individual SNP or
the score for type 2 diabetes, adjusted for age and sex) were
compared by Student’s t test, as previously described by
Freathy et al. [20]. We used the same samples to make the
comparison for each individual SNP or the genetic
predisposition score. Figure 1 illustrates this comparison
using the genetic predisposition score as an example. We
repeated the analysis using both prevalent type 2 diabetes at
baseline and incident type 2 diabetes during follow-up.
We estimated the power that our study had to observe a
nominally significant association (p<0.05) of each individual
SNP or the genetic predisposition score with type 2 diabetes,
based on the expected effect size (and its SE) of each
individual SNP or the score on type 2 diabetes. The power
was estimated using the following coding: power=1−CDF
[‘normal’,1 . 9 6 −(absolute value of expected effect size/
SE)], where CDF is the cumulative distribution function.
We also examined the sex differences in the associations
by including an interaction term between sex and SNP
(or the score) in the respective models. All analyses were
performed using SAS version 9.1 (SAS Institute, Cary,
NC, USA).
Results
The effectsizes ofindividualSNPs onBMIatbaselineranged
from 0.058 to 0.328 kg/m
2, with rs1121980 in the FTO locus
showing the largest effect size and rs7647305 in the ETV5
locus the smallest (Table 2). Each additional BMI-increasing
allele in the genetic predisposition score was associated with
0.153 (95% CI 0.129–0.177) kg/m
2 (p=5.85×10
−36)i n -
crease in BMI.
Genetic 
score
BMI
Type 2 
diabetes
β GB =0.153 (0.129, 0.177)
p=5.85×10 −36
β BD =0.187 (0.170, 0.203)
p=6.76×10 −105
β  O=0.040 (0.005, 0.075)
βE=0.029 (0.023, 0.034)
p value for difference between β   E and β   O=0.519
Difference between βE and β   O=−0.011 (−0.047, 0.024)
Fig. 1 Illustration of the triangular relationship among the genetic
predisposition score, BMI, and type 2 diabetes. βGB represents the
effect size of the score on BMI, βBD the effect size of BMI on the risk
of developing type 2 diabetes (lnOR), βO the observed effect size of
the score on type 2 diabetes, and βE the expected effect size of the
score on type 2 diabetes based on βGB and βBD. βE and βO were
compared by Student’s t test. Numbers in parentheses are 95% CIs
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Diabetologia (2011) 54:776–782 779Overall, each unit (kg/m
2) increase in BMI was
associated with an OR of 1.203 (95% CI 1.185–1.225,
p=5.62×10
−108) for developing type 2 diabetes during
follow-up. The odds ratios were similar if both prevalent
cases at baseline and incident cases during follow-up were
included (OR 1.174, 95% CI 1.158–1.190, p=1.44×10
−116).
Among the 12 SNPs, eight, in or near TMEM18,
GNPDA2, BDNF, FAIM2, SH2B1, FTO, MC4R and
KCTD15, did not show an association with type 2 diabetes.
However, the effect of these SNPs was directionally
consistent as expected from their associations with BMI
(OR range 1.039–1.148; Table 2). Further adjustment of
these associations for BMI attenuated this positive trend.
Four SNPs, in or near NEGR1, SEC16B, ETV5 and
MTCH2, tended to be associated with a decreased risk of
type 2 diabetes which was directionally opposite to what
would be expected based on their BMI-increasing effect
(OR range 0.879–0.995). The BMI-increasing allele of
rs7647305 in the ETV5 locus was associated with a
decreased risk of developing type 2 diabetes (p=0.048).
Further adjustment for BMI somewhat strengthened this
inverse association (Table 2).
The genetic predisposition score, which considers the
collective contribution of the 12 SNPs, showed a positive
association with incident type 2 diabetes. Each additional
BMI-increasing allele in the genetic predisposition score
was associated with a 4.1% (95% CI 0.5–7.8%) increased
odds of developing type 2 diabetes during follow-up (OR
1.041, 95% CI 1.005–1.078; p=0.02). Adjustment for BMI
completely abolished this association (OR 1.003, 95% CI
0.967–1.039, p=0.89).
The associations of individual SNPs or predisposition
score with the incidence of type 2 diabetes were not
different from the associations expected based on the
observed associations between these SNPs (or the score)
and BMI and the association between BMI and type 2
diabetes, except for rs7647305 in the ETV5 locus (p=0.02;
Table 2).
Based on the expected effect size of individual SNPs or
the genetic predisposition score on type 2 diabetes, we had
sufficient power (>83%) to observe a nominally significant
(p<0.05) association with type 2 diabetes for the genetic
predisposition score and for seven SNPs in or near
SEC16B, TMEM18, GNPDA2, BDNF, FAIM2, FTO and
MC4R, and reasonable power (>62%) for two SNPs (near
NEGR1 and SH2B1; ESM Table 2).
We repeated the same analyses using both prevalent
cases at baseline and incident cases during follow-up (ESM
Table 3). The results were largely similar to those of
analyses with incident cases only, except that the FTO locus
showed a nominal association with an increased risk of type
2 diabetes (p=0.04), whereas the association of the ETV5
locus with type 2 diabetes was no longer observed
(p=0.19). Also, the observed and expected associations of
SNPs or the score with type 2 diabetes were no longer
different (p≥0.15).
There were no sex differences in the associations of
individual SNPs or the score with type 2 diabetes (p>0.08
for all comparisons).
Discussion
In this large population-based, prospective study with an
average follow-up period of 12.9 years, we examined
whether the recently identified BMI loci affect the risk of
type 2 diabetes independently of, or mediated through,
their effects on BMI. Despite the fact that our study was
sufficiently powered (>83%) for the majority of the
SNPs, we did not observe associations of individual
SNPs with type 2 diabetes, except for the ETV5 locus,
w h i c hs h o w e dad i r e c t i o n a l l yo p p o s i t ea s s o c i a t i o nw i t h
type 2 diabetes (p=0.048). Although the BMI-increasing
alleles of most of the SNPs showed a directionally
consistent (increasing) trend with the risk of type 2
diabetes, adjustment for BMI attenuated this trend. The
overall genetic predisposition to obesity, as estimated by
the combination of BMI-increasing alleles across the 12
SNPs, showed an increased risk of developing type 2
diabetes. Each additional risk allele in the genetic
predisposition score was associated with a 4% increased
odds for developing type 2 diabetes during follow-up.
However, consistent with the individual SNPs analyses,
this association was mediated by the effect of the genetic
predisposition score on BMI, as adjustment for BMI
completely abolished the association. Thus, we observed
no marginal effects of the genetic predisposition score on
the risk of developing type 2 diabetes and the observed
attenuation by BMI was in line with what was expected
based on the genetic effects on BMI. Our results support
the established causal and positive association between
increased BMI and type 2 diabetes.
Information regarding the associations of individual
SNPs with type 2 diabetes might improve our understand-
ing of the heterogeneity of the obesity–type 2 diabetes
relationship. Such heterogeneity cannot be captured by the
genetic predisposition score as it is a composite of genetic
variants that might represent a variety of biological path-
ways. Of the 12 loci examined in this study, only the FTO
locus was known to be associated with type 2 diabetes, but
this association is fully mediated by FTO’s BMI-increasing
effect [8, 21].
Two GWA studies of BMI reported on the associations
betweenthe identifiedBMI lociandthe riskoftype2diabetes
[11, 12]. In the study by Willer et al. [11], results on the
association between eight BMI loci and the risk of type 2
780 Diabetologia (2011) 54:776–782diabetes were obtained from the DIAGRAM consortium
[22]. This meta-analysis of GWA studies of type 2 diabetes
case–control studies (ncases=4,549, ncontrols=5,579) con-
firmed the association between variation in FTO (p=6.8×
10
−7) and type 2 diabetes, and also found evidence for the
BMI-increasing alleles of variants near TMEM18 (p=7.6×
10
−4)a n dGNPDA2 (p=6.6×10
−5) with an increased risk of
type 2 diabetes [22]. These observations seemed consistent
with the trends observed in the current study, but a thorough
comparison was not possible as no effect sizes or analyses
adjusted for BMI have been reported. In addition, no
associations between the five other BMI loci (NEGR1,
MTCH2, SH2B1, MC4R and KCTD15)w e r ef o u n d[ 22].
Thorleifsson et al. [12] reported on ten BMI loci and the risk
of type 2 diabetes (ncases=3,876, ncontrols=28,031) and
confirmed the association between FTO variants and risk
of obesity, but, unlike in the DIAGRAM consortium, no
association was observed for the TMEM18 locus. The BMI-
increasing allele of the FAIM2 locus was found to be
associated with type 2 diabetes (OR 1.11, p=2.3×10
−4)a n d
adjustment for BMI only slightly attenuated the association
(OR 1.08, p=0.009) [12]. The FAIM2 variant in our study
showed no association with type 2 diabetes, either without
(OR 1.02, p=0.69) or with adjustment (OR 0.98, p=0.78)
for BMI. The BMI-increasing allele of rs7647305 in the
ETV5 locus, for which we found suggestive evidence
(p=0.048) for a protective effect, was associated with an
increased risk of type 2 diabetes (p=0.04) in Thorleifsson et
al. [12]. Apart from a weak association (p=0.04) for the
NEGR1 variant, none of the other variants (in or near
SEC16B, BDNF, SH2B1, MC4R and KCTD15)s t u d i e db y
Thorleifsson et al. showed association with the risk of type 2
diabetes. In summary, the currently available literature
supports a robust association between the BMI-increasing
allele of variants in the FTO locus with an increased risk of
type 2 diabetes, which is abolished after adjustment for BMI,
whereas no associations have been observed for variants in
or near SEC16B, BDNF, MTCH2, SH2B1, MC4R and
KCTD15. Results for loci in or near NEGR1, TMEM18,
ETV5, GNPDA2 and FAIM2 remain inconsistent across
studies [12, 22], which could, in part, be due to differences
in study design (e.g. population-based vs case–control,
incident vs prevalent) or environmental factors.
The reason for the lack of overall significant findings for
individual SNPs is not clear. Our study had sufficient power
to observe a nominally significant association between most
SNPs and type 2 diabetes. It can be speculated that the
observed SNP–diabetes associations may have been atten-
uated by other factors, which reduce the power for finding
associations in our study. It is also possible that there is true
heterogeneity in the biological pathways that underlie the
observed SNP–BMI associations, which may explain the
lack of associations between obesity SNPs and type 2
diabetes. If such heterogeneity indeed exists, it may explain
the lack of associations between obesity SNPs and type 2
diabetes in our study. It may also help explain why some
obese individuals do not experience obesity-related meta-
bolic consequences; i.e. they have the ‘healthy obesity
phenotype’ [23–25]. Future large studies or meta-analyses
of multiple studies are needed to establish the associations
of most of the individual SNPs with type 2 diabetes.
Recent GWA studies of type 2 diabetes have emphasised
the importance of beta cell function in the development of
type 2 diabetes [26, 27]. However, the association of the
genetic predisposition score with type 2 diabetes and its
abolishment after adjustment for BMI in the current study
also emphasise the importance of obesity in the develop-
ment of type 2 diabetes and infer causality between the two
conditions. Our results also indicate that, in general, genetic
variants for obesity do not have an independent effect on
the risk of type 2 diabetes.
Our results suggest that the overall genetic susceptibility
to obesity, estimated by the genetic predisposition score,
increases susceptibility to type 2 diabetes. However, as we
have previously shown that the genetic predisposition score
explains less than 1% of the variation in BMI and has
limited predictive value for obesity [16], its contribution to
variation in type 2 diabetes risk is likely to be similar or
even less. Taken together, the results suggest that while the
genetic predisposition score has limited clinical value, it
can be used as an instrumental variable in the context of
Mendelian randomisation.
In conclusion, the genetic predisposition to obesity
leads to an increased risk of type 2 diabetes in our large
population-based, longitudinal cohort with an average
follow-up period of 12.9 years. Our observations suggest
a causal relationship between increased BMI/obesity and
type 2 diabetes and emphasise the importance of obesity
in the development of type 2 diabetes. Larger studies will
be required to convincingly establish associations be-
tween individual SNPs and type 2 diabetes, and to
identify subtle differences between these associations that
might enhance our insight into the biological pathways
they implicate.
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